Nycomed filed a marketing authorisation application with the European Medicines Agency (EMEA) for an intranasal fentanyl spray in Europe on December 7, 2007. It is seeking approval for the indication of managing breakthrough pain (BTP) in adults already receiving maintenance opioid therapy for cancer pain. If approved, the centralised filing could allow Nycomed to be the first to enter the market in 29 European countries with an intranasally administered formulation of fentanyl.
For further information:Media:Tobias Cottmann, Director External CommunicationsTel.: +41 4455/515-10
Medical professionals and scientific media:Ulf Jonson, International Product ManagerTel.: +45 4677/10-78
Notes for editors:A background document focusing on breakthrough cancer pain is available on request. Please contact Ulf Jonson (contact above).
Healthcare professionals can find more information about breakthrough pain at https://www.gesundheitsindustrie-bw.dewww.breakthroughpain.eu/